What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Fathom Holdings (FTHM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Centrus Energy Corp. (LEU) have what it takes to be a top stock pick for momentum investors? Let's find out.
BXP is set to gain from a premium office portfolio, a diverse tenant base, strong lab asset demand and a healthy balance sheet despite high supply.
The Vanguard Dividend Appreciation ETF isn’t the highest-paying income ETF, but there’s a lot to like about it. The Vanguard International High Dividend Yield ETF has an excellent yield and cheap valuation. The Vanguard Real Estate ETF could be a big winner as interest rates fall.
Diving into two beaten-down S&P 500 stocks--Thermo Fisher Scientific and Lululemon--to consider buying now for huge upside.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does NBT Bancorp (NBTB) have what it takes? Let's find out.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Equinix (EQIX) have what it takes? Let's find out.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Barclays (BCS) have what it takes? Let's find out.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Popular (BPOP) have what it takes? Let's find out.